Issaka Maman
University of Lomé
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Issaka Maman.
PLOS Neglected Tropical Diseases | 2015
Richard Phillips; Delphin Mavinga Phanzu; Marcus Beissner; Kossi Badziklou; Elysée Kalundieko Luzolo; Fred Stephen Sarfo; Wemboo Afiwa Halatoko; Yaw Ampem Amoako; Michael Frimpong; Abass Mohammed Kabiru; Ebekalisai Piten; Issaka Maman; Bawimodom Bidjada; Adjaho Koba; Koffi Somenou Awoussi; Basile Kobara; Jörg Nitschke; Franz Xaver Wiedemann; Abiba Banla Kere; Ohene Adjei; Thomas Löscher; Bernhard Fleischer; Gisela Bretzel; Karl-Heinz Herbinger
Background The only available vaccine that could be potentially beneficial against mycobacterial diseases contains live attenuated bovine tuberculosis bacillus (Mycobacterium bovis) also called Bacillus Calmette-Guérin (BCG). Even though the BCG vaccine is still widely used, results on its effectiveness in preventing mycobacterial diseases are partially contradictory, especially regarding Buruli Ulcer Disease (BUD). The aim of this case-control study is to evaluate the possible protective effect of BCG vaccination on BUD. Methodology The present study was performed in three different countries and sites where BUD is endemic: in the Democratic Republic of the Congo, Ghana, and Togo from 2010 through 2013. The large study population was comprised of 401 cases with laboratory confirmed BUD and 826 controls, mostly family members or neighbors. Principal Findings After stratification by the three countries, two sexes and four age groups, no significant correlation was found between the presence of BCG scar and BUD status of individuals. Multivariate analysis has shown that the independent variables country (p = 0.31), sex (p = 0.24), age (p = 0.96), and presence of a BCG scar (p = 0.07) did not significantly influence the development of BUD category I or category II/III. Furthermore, the status of BCG vaccination was also not significantly related to duration of BUD or time to healing of lesions. Conclusions In our study, we did not observe significant evidence of a protective effect of routine BCG vaccination on the risk of developing either BUD or severe forms of BUD. Since accurate data on BCG strains used in these three countries were not available, no final conclusion can be drawn on the effectiveness of BCG strain in protecting against BUD. As has been suggested for tuberculosis and leprosy, well-designed prospective studies on different existing BCG vaccine strains are needed also for BUD.
PLOS Neglected Tropical Diseases | 2015
Marcus Beissner; Richard Phillips; Florian Battke; Malkin Bauer; Kossi Badziklou; Fred Stephen Sarfo; Issaka Maman; Agata Rhomberg; Ebekalisai Piten; Michael Frimpong; Kristina Lydia Huber; Dominik Symank; Moritz Jansson; Franz Xaver Wiedemann; Abiba Banla Kere; Karl-Heinz Herbinger; Thomas Löscher; Gisela Bretzel
Background As the major burden of Buruli ulcer disease (BUD) occurs in remote rural areas, development of point-of-care (POC) tests is considered a research priority to bring diagnostic services closer to the patients. Loop-mediated isothermal amplification (LAMP), a simple, robust and cost-effective technology, has been selected as a promising POC test candidate. Three BUD-specific LAMP assays are available to date, but various technical challenges still hamper decentralized application. To overcome the requirement of cold-chains for transport and storage of reagents, the aim of this study was to establish a dry-reagent-based LAMP assay (DRB-LAMP) employing lyophilized reagents. Methodology/Principal Findings Following the design of an IS2404 based conventional LAMP (cLAMP) assay suitable to apply lyophilized reagents, a lyophylization protocol for the DRB-LAMP format was developed. Clinical performance of cLAMP was validated through testing of 140 clinical samples from 91 suspected BUD cases by routine assays, i.e. IS2404 dry-reagent-based (DRB) PCR, conventional IS2404 PCR (cPCR), IS2404 qPCR, compared to cLAMP. Whereas qPCR rendered an additional 10% of confirmed cases and samples respectively, case confirmation and positivity rates of DRB-PCR or cPCR (64.84% and 56.43%; 100% concordant results in both assays) and cLAMP (62.64% and 52.86%) were comparable and there was no significant difference between the sensitivity of the assays (DRB PCR and cPCR, 86.76%; cLAMP, 83.82%). Likewise, sensitivity of cLAMP (95.83%) and DRB-LAMP (91.67%) were comparable as determined on a set of 24 samples tested positive in all routine assays. Conclusions/Significance Both LAMP formats constitute equivalent alternatives to conventional PCR techniques. Provided the envisaged availability of field friendly DNA extraction formats, both assays are suitable for decentralized laboratory confirmation of BUD, whereby DRB-LAMP scores with the additional advantage of not requiring cold-chains. As validation of the assays was conducted in a third-level laboratory environment, field based evaluation trials are necessary to determine the clinical performance at peripheral health care level.
PLOS Neglected Tropical Diseases | 2012
Marcus Beissner; Ebekalisai Piten; Issaka Maman; Dominik Symank; Moritz Jansson; Jörg Nitschke; Komi Amekuse; Basil Kobara; Franz Xaver Wiedemann; Harald Hoffmann; Adolf Diefenhardt; Kossi Badziklou; Abiba Banla Kere; Thomas Löscher; Gisela Bretzel
1 Department of Infectious Diseases and Tropical Medicine (DITM), University Hospital, Ludwig-Maximilians University, Munich, Germany, 2 Centre Hospitalier Régional Maritime (CHR Maritime), Tsévié, Togo, 3 Institut National d’Hygiène (INH), Lomé, Togo, 4 German Leprosy and Tuberculosis Relief Association (DAHW), Würzburg, Germany, 5 German Leprosy and Tuberculosis Relief Association (DAHW), Togo office, Lomé, Togo, 6 Programme National de Lutte contre L’Ulcère de Buruli – Lèpre et Pian (PNLUB-LP), Lomé, Togo, 7 Institute of Microbiology and Laboratory Medicine, Pneumological Teaching Hospital of the University of Munich, Gauting, Germany
PLOS Neglected Tropical Diseases | 2013
Marcus Beissner; Kristina Lydia Huber; Kossi Badziklou; Wemboo Afiwa Halatoko; Issaka Maman; Felix Vogel; Bawimodom Bidjada; Koffi Somenou Awoussi; Ebekalisai Piten; Kerstin Helfrich; Carolin Mengele; Jörg Nitschke; Komi Amekuse; Franz Xaver Wiedemann; Adolf Diefenhardt; Basile Kobara; Karl Heinz Herbinger; Abiba Banla Kere; Mireille Prince-David; Thomas Löscher; Gisela Bretzel
Background In a previous study PCR analysis of clinical samples from suspected cases of Buruli ulcer disease (BUD) from Togo and external quality assurance (EQA) for local microscopy were conducted at an external reference laboratory in Germany. The relatively poor performance of local microscopy as well as effort and time associated with shipment of PCR samples necessitated the implementation of stringent EQA measures and availability of local laboratory capacity. This study describes the approach to implementation of a national BUD reference laboratory in Togo. Methodology Large scale outreach activities accompanied by regular training programs for health care professionals were conducted in the regions “Maritime” and “Central,” standard operating procedures defined all processes in participating laboratories (regional, national and external reference laboratories) as well as the interaction between laboratories and partners in the field. Microscopy was conducted at regional level and slides were subjected to EQA at national and external reference laboratories. For PCR analysis, sample pairs were collected and subjected to a dry-reagent-based IS2404-PCR (DRB-PCR) at national level and standard IS2404 PCR followed by IS2404 qPCR analysis of negative samples at the external reference laboratory. Principal Findings The inter-laboratory concordance rates for microscopy ranged from 89% to 94%; overall, microscopy confirmed 50% of all suspected BUD cases. The inter-laboratory concordance rate for PCR was 96% with an overall PCR case confirmation rate of 78%. Compared to a previous study, the rate of BUD patients with non-ulcerative lesions increased from 37% to 50%, the mean duration of disease before clinical diagnosis decreased significantly from 182.6 to 82.1 days among patients with ulcerative lesions, and the percentage of category III lesions decreased from 30.3% to 19.2%. Conclusions High inter-laboratory concordance rates as well as case confirmation rates of 50% (microscopy), 71% (PCR at national level), and 78% (including qPCR confirmation at external reference laboratory) suggest high standards of BUD diagnostics. The increase of non-ulcerative lesions, as well as the decrease in diagnostic delay and category III lesions, prove the effect of comprehensive EQA and training measures involving also procedures outside the laboratory.
Journal of Clinical Microbiology | 2014
Moritz Jansson; Marcus Beissner; Richard Phillips; Kossi Badziklou; Ebekalisai Piten; Issaka Maman; Fred Stephen Sarfo; Kristina Lydia Huber; Agata Rhomberg; Dominik Symank; Magdalena Wagner; Franz Xaver Wiedemann; Jörg Nitschke; Abiba Banla Kere; Karl-Heinz Herbinger; Ohene Adjei; Thomas Löscher; Gisela Bretzel
ABSTRACT This study evaluates a novel assay for detecting rifampin resistance in clinical Mycobacterium ulcerans isolates. Although highly susceptible for PCR inhibitors in 50% of the samples tested, the assay was 100% M. ulcerans specific and yielded >98% analyzable sequences with a lower limit of detection of 100 to 200 copies of the target sequence.
PLOS Neglected Tropical Diseases | 2018
Issaka Maman; Tchadjobo Tchacondo; Abiba Banla Kere; Marcus Beissner; Kossi Badziklou; Ekanao Tedihou; Edith Nyaku; Komi Amekuse; Franz Xaver Wiedemann; D. S. Karou; Gisela Bretzel
Background Buruli Ulcer (BU) is a neglected tropical skin infection caused by Mycobacterium ulcerans. Residence near aquatic areas has been identified as an important source of transmission of M. ulcerans with increased risk of contracting Buruli ulcer. However, the reservoir and the mode of transmission are not yet well known. The aim of this study was to identify the presence of M. ulcerans in the environment and its relationship with Buruli ulcer occurrence in Zio and Yoto districts of the maritime region in south Togo. Methods A total of 219 environmental samples including soil (n = 119), water (n = 65), biofilms/plants (n = 29) and animals’ feces (n = 6) were collected in 17 villages of Zio and Yoto districts of the maritime region in Togo. DNA of M. ulcerans including IS2404 and IS2606 insertions sequences and mycolactone ketoreductase-B gene (KR-B) was detected using real time PCR amplification (qPCR) technique. In parallel, clinical samples of patients were tested to establish a comparison of the genetic profile of M. ulcerans between the two types of samples. A calibration curve was generated for IS2404 from a synthetic gene of M. ulcerans Transposase pMUM001, the plasmid of virulence. Results In the absence of inhibition of the qPCR, 6/219 (2.7%) samples were tested positive for M. ulcerans DNA containing three sequences (IS2404/IS2606/KR-B). Positive samples of M. ulcerans were consisting of biofilms/plants (3/29; 10.3%), water (1/65; 1.7%) and soil (2/119; 1.5%). Comparative analysis between DNA detected in environmental and clinical samples from BU patients showed the same genetic profile of M. ulcerans in the same environment. All these samples were collected in the environment of Haho and Zio rivers in the maritime region. Conclusion This study confirms the presence of M. ulcerans in the environment of the Zio and Yoto districts of the maritime region of Togo. This may explain partially, the high rates of Buruli ulcer patients in this region. Also, water, plants and soil along the rivers could be possible reservoirs of the bacterium. Therefore, Haho and Zio rivers could be potential sources of infection with M. ulcerans in humans in these districts.
BMC Public Health | 2014
Issaka Maman; Kossi Badziklou; Essoya D Landoh; Afiwa W Halatoko; Talla N Nzussouo; Gabriel N Defang; Tsidi Tamekloe; Pamela J Kennedy; Williams Thelma; Komlan Kossi; Zoulkarneiri Issa; Abiba Banla Kere
BMC Infectious Diseases | 2018
Issaka Maman; Tchadjobo Tchacondo; Abiba Banla Kere; Ebekalisai Piten; Marcus Beissner; Yiragnima Kobara; Komlan Kossi; Kossi Badziklou; Franz Xaver Wiedemann; Komi Amekuse; Gisela Bretzel; D. S. Karou
BMC Infectious Diseases | 2017
Ndahwouh Talla Nzussouo; Jazmin Duque; Adebayo Adedeji; Daouda Coulibaly; Samba O. Sow; Zekiba Tarnagda; Issaka Maman; Adamou Lagare; Sonia Makaya; Mohamed Brahim Elkory; Herve Kadjo Adje; Paul Alhassan Shilo; Boubou Tamboura; Assana Cissé; Kossi Badziklou; Halima Boubacar Maïnassara; Ahmed Ould Bara; Adama Mamby Keita; Thelma Williams; Ann Moen; Marc-Alain Widdowson; Meredith McMorrow
Journées Scientifiques Internationales de Lomé, (JSIL 2016) XVIIe édition | 2016
Issaka Maman; Tchadjobo Tchacondo; Wemboo Afiwa Halatoko; Komi Amekuse; Abiba Banla Kere; D. S. Karou